ADOCIA's Share Capital Evolution: A Year in Review

In the dynamic world of biopharmaceuticals, Adocia (Euronext Paris: FR0011184241 – ADOC) has been making waves with its innovative therapeutic solutions for diabetes and obesity. As the company continues to grow and evolve, so does its share capital. Let's take a look at how ADOCIA's number of shares and voting rights have changed over the past year.

As of October 31st, 2024, ADOCIA's total number of outstanding shares stood at 15,471,638, marking a significant increase from the previous year. This growth can be attributed to various factors, including the issuance of new shares, the exercise of warrants and options, and potential acquisitions or mergers. The company's market capitalization and enterprise value have also been impacted by this change in shares outstanding, with a dilution in market capitalization and enterprise value per share.

Despite the dilution, ADOCIA's overall value remains robust, with a market cap of EUR 92.92 million and an enterprise value of EUR 95.86 million. The company's focus on research and development, as well as its strategic partnerships, continues to drive its growth and innovation in the biopharmaceutical sector.

In conclusion, ADOCIA's share capital evolution over the past year reflects the company's commitment to growth and expansion. As the company continues to develop its therapeutic solutions, investors should keep an eye on its share capital and voting rights, as well as its overall financial performance and market conditions.